KINTARA THERAPEUTICS INC (KTRA) Stock Income Statement
USA - NASDAQ:KTRA - US49720K2006 - Common Stock
0.2154 USD
-0.01 (-6.31%)
0.225 USD
+0.01 (+4.46%)
| 2024 (2024-6-30) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | 2020 (2020-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 8.45M | 14.80M | 22.68M | 37.67M | 8.15M | |||
| Research and Development | 2.66M | 9.31M | 15.17M | 27.91M | 3.63M | |||
| Selling, General, and Administrative Expenses | 5.79M | 5.49M | 7.51M | 9.76M | 4.51M | |||
| Operating Income | -8.45M | -14.80M | -22.68M | -37.67M | -8.15M | |||
| Interest Income/Expense | 131.00K | 150.00K | 20.00K | -130.00K | 70.00K | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | null | 0 | -500.00K | -1.05M | |||
| Income Before Taxes | -8.32M | -14.65M | -22.66M | -38.30M | -9.13M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -8.50M | -15.02M | -25.13M | -41.50M | -9.13M | |||
| EBITDA | -8.40M | -14.74M | -22.62M | -37.64M | -8.14M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.32259 | -9.27 | -25.9 | -79.8 | -43.47 | |||
| Non GAAP EPS | null | -9.49 | -25.5 | -39 | null | |||
| Statistics | ||||||||
All data in USD